BioAtla, Inc. (BCAB)
NASDAQ: BCAB · IEX Real-Time Price · USD
1.620
-0.080 (-4.71%)
Jul 26, 2024, 4:00 PM EDT - Market closed
BioAtla Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
65
Market Cap
77.95M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBCAB News
- 1 day ago - BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day - GlobeNewsWire
- 2 months ago - BioAtla to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 2 months ago - BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 2 months ago - BioAtla to Participate in the Citizens JMP Life Sciences Conference - GlobeNewsWire
- 2 months ago - BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024 - GlobeNewsWire
- 2 months ago - BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors - GlobeNewsWire
- 3 months ago - BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire